Epo levels and immunophenotype of myeloid blasts at start of Epo/G-CSF treatment
| . | Epo < 100 U/L . | Epo > 100 U/L . | ||
|---|---|---|---|---|
| nFCM . | aFCM . | nFCM . | aFCM . | |
| Responders | 13 | 2 | 3 | 0 |
| Nonresponders | 1 | 5 | 6 | 16 |
| Response rate | 94% | 29% | 33% | 0% |
| . | Epo < 100 U/L . | Epo > 100 U/L . | ||
|---|---|---|---|---|
| nFCM . | aFCM . | nFCM . | aFCM . | |
| Responders | 13 | 2 | 3 | 0 |
| Nonresponders | 1 | 5 | 6 | 16 |
| Response rate | 94% | 29% | 33% | 0% |
aFCM indicates aberrant immunophenotype of myeloid blasts; Epo, erythropoietin; G-CSF, granulocyte-colony-stimulating factor; and nFCM, normal immunophenotype of myeloid blasts.